(Q47273564)

13 January 2018

title

NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine (English)

1 reference

13 January 2018

author

William G. Haynes

12

1 reference

13 January 2018

Arne Astrup

8

object named as

Arne Astrup

1 reference

13 January 2018

16

Steven B Heymsfield

1 reference

13 January 2018

1

Ngozi Erondu

1 reference

13 January 2018

author name string

Carol Addy

2

1 reference

13 January 2018

Kaifeng Lu

3

1 reference

13 January 2018

Madhuja Mallick

4

1 reference

13 January 2018

Bret Musser

5

1 reference

13 January 2018

Ira Gantz

6

1 reference

13 January 2018

Joseph Proietto

7

1 reference

13 January 2018

Søren Toubro

9

1 reference

13 January 2018

Aila M Rissannen

10

1 reference

13 January 2018

Serena Tonstad

11

1 reference

13 January 2018

Keith M Gottesdiener

13

1 reference

13 January 2018

Keith D Kaufman

14

1 reference

13 January 2018

John M Amatruda

15

1 reference

13 January 2018

publication date

1 August 2007

1 reference

13 January 2018

published in

Obesity

1 reference

13 January 2018

volume

15

1 reference

13 January 2018

issue

8

1 reference

13 January 2018

page(s)

2027-2042

1 reference

13 January 2018

Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Assessing Impact of Weight on Quality of Life

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Orlistat, a new lipase inhibitor for the management of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Sibutramine and the management of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

The efficacy and safety of sibutramine for weight loss: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

A systematic review of the clinical effectiveness of orlistat used for the management of obesity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Central nervous system control of food intake

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

From lesions to leptin: hypothalamic control of food intake and body weight.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

A receptor subtype involved in neuropeptide-Y-induced food intake

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

[D-Trp(34)] neuropeptide Y is a potent and selective neuropeptide Y Y(5) receptor agonist with dramatic effects on food intake

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Food intake inhibition and reduction in body weight gain in lean and obese rodents treated with GW438014A, a potent and selective NPY-Y5 receptor antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Characterization of Neuropeptide Y (NPY) Y5 Receptor-Mediated Obesity in Mice: Chronic Intracerebroventricular Infusion ofd-Trp34NPY

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Design and synthesis of the potent, orally available, brain-penetrable arylpyrazole class of neuropeptide Y5 receptor antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Role of the Y5 neuropeptide Y receptor in feeding and obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Lipoprotein distribution and composition in obesity: their association with central adiposity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

The MOS 36-ltem Short-Form Health Survey (SF-36)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

EuroQol--a new facility for the measurement of health-related quality of life

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Modern statistical methods for handling missing repeated measurements in obesity trial data: beyond LOCF.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

The serotonin (5-HT) antagonist methysergide increases neuropeptide Y (NPY) synthesis and secretion in the hypothalamus of the rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Differential effects of the 5-HT 1B/2C receptor agonist mCPP and the 5-HT1A agonist flesinoxan on hypothalamic neuropeptide Y in the rat: evidence that NPY may mediate serotonin's effects on food intake

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Acute fenfluramine administration reduces neuropeptide Y concentrations in specific hypothalamic regions of the rat: possible implications for the anorectic effect of fenfluramine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.242

https://api.fatcat.wiki/v0/release/fzleqdkjb5cr7pzeylfqvnuq2m

31 March 2020

Identifiers

1 reference

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_fzleqdkjb5cr7pzeylfqvnuq2m

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fzleqdkjb5cr7pzeylfqvnuq2m

mapped directly with Wikidata item

30 July 2022

based on heuristic

1 reference

https://api.fatcat.wiki/v0/release/fzleqdkjb5cr7pzeylfqvnuq2m